TCM
NPCE icon

Topline Capital Management’s Neuropace NPCE Stock Holding History

Topline Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
+80,945
New +$1.21M 0.18% 34

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Topline Capital Management's NPCE Position: Q1 2026 in Review

Topline Capital Management opened a new position in Neuropace (NPCE) in Q1 2026: 80,945 shares worth $1.06M. The stake represents 0.18% of the portfolio and ranks #34 among its holdings.

113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Topline Capital Management held 80,945 shares of Neuropace worth $1.06M as of Q1 2026.
  • Neuropace was a new Topline Capital Management position in Q1 2026.
  • Neuropace made up 0.18% of Topline Capital Management's portfolio in Q1 2026, its #34 holding.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Topline Capital Management's 13F filing for Q1 2026, filed 15 May 2026.